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Abstract
Background: This study assessed the association of alanine-aminotransferase (ALT) and hepatitis C virus (HCV) RNA
levels with pro-inflammatory and pro-fibrogenic cytokines and chemokines during acute HCV infection to provide
further insight into the potential HCV immunopathogenesis.
Methods: Participants in the ATAHC study, a prospective study of recent HCV infection, with detectable HCV RNA
at the time of HCV detection were included. Plasma levels of 27 cytokines and chemokines were measured and
their correlation with ALT and HCV RNA levels were assessed. Log10 transformed cytokines and ALT values were
used in the analysis.
Results: Among 117 individuals, the plasma levels of interferon-gamma inducible protein-10 (IP-10) and
macrophage inflammatory protein-1beta (MIP-1β) were positively correlated with ALT levels (IP-10: r = 0.42, P < 0.001;
MIP-1β: r = 0.29, P = 0.001) and HCV RNA levels (IP-10: rs = 0.44, P < 0.001; MIP-1β: rs = 0.43, P < 0.001). Using linear
regression, after adjusting for sex, age, infection duration, symptomatic infection, HIV co-infection, interferon-lambda
rs12979860 genotype, HCV genotype, and assay run, higher ALT levels (β = 0.20; 95 % CI: 0.07, 0.32; P = 0.002) and HCV
RNA levels >400,000 IU/mL (vs. <8,500 IU/mL; β = 0.16; 95 % CI: 0.03, 0.28; P = 0.014) were independently associated
with higher IP-10 levels. HCV RNA levels >400,000 IU/mL (vs. <8,500 IU/mL; β = 0.16; 95 % CI: 0.01, 0.31; P = 0.036) were
associated with higher MIP-1β levels.
Conclusions: During acute HCV infection, high ALT and HCV RNA levels were associated with increased IP-10 levels,
while high HCV RNA levels were also associated with increased MIP-1β levels. These data suggest that IP-10 and MIP-1β
may have a role in HCV immuno-pathogenesis starting early in acute HCV infection.
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Background
The majority of individuals with acute hepatitis C virus
(HCV) infection progress to chronic infection [1, 2], and
are at increased risk of liver fibrosis progression [3, 4].
Several studies have demonstrated that while elevation
of alanine aminotransferase (ALT) is an important pre-
dictor of the development and progression of liver fibro-
sis in chronic HCV infection, HCV RNA levels have
limited role in this regard (reviewed in [4, 5]). This sup-
ports a hypothesis suggesting a more important role of
intra-hepatic inflammation in development and progres-
sion of liver fibrosis than direct HCV cytotoxicity in
HCV infection.
In a longitudinal study investigating six individuals
with acute HCV infection followed from HCV acquisi-
tion up to 30 years following infection, rapid liver dis-
ease progression correlated with persistent elevation of
ALT levels [6]. These data suggest that a persistently
high ALT during acute HCV infection is a marker for
enhanced liver disease progression in the later stages of
chronic HCV infection. Further investigation of the fac-
tors associated with ALT levels in acute HCV infection
may provide a better understanding of immuno-
pathogenesis of HCV infection.
The underling mechanisms promoting the develop-
ment of hepatic inflammation in HCV infection have
not been well understood. Cytokines and chemokines
may have a role in the development of HCV-induced
liver inflammation (reflected by ALT elevation) given
their role in recruitment, accumulation, and localisation
of inflammatory cells in the liver following HCV infec-
tion (reviewed in [7, 8]). In the setting of chronic HCV
infection, several studies identified a correlation between
ALT and/or HCV RNA levels with peripheral concentra-
tions of several cytokines [8–16] while the up-regulation
of intra-hepatic expression of a number of cytokines
have been reported in patients with HCV-induced
advanced liver inflammation and fibrosis [17–19]. How-
ever, in the setting of acute HCV infection, there are
relatively little data on the role of cytokines and chemo-
kines in liver inflammation and the association of cyto-
kines and chemokines with ALT or HCV RNA levels,
while the existing studies have been limited by small
sample sizes [6, 20–23].
The present study was undertaken to assess the associ-
ation of ALT and HCV RNA levels with plasma levels of
pro-inflammatory and pro-fibrogenic cytokines and che-
mokines at the time of HCV detection in recent HCV
infection (i.e., acute and early chronic).
Results
Participant characteristics
A total of 117 individuals with recent HCV infection
were included in the study. Background characteristics
of the study population are summarized in Table 1. In
brief, the median age was 34 years, 75 % were male,
42 % had symptomatic illness at HCV detection, 38 %
had HIV co-infection, and 57 % were infected with HCV
genotype 1. Median ALT and HCV RNA levels at the
time of HCV detection were 145 IU/L [inter-quartile
range (IQR): 73 – 385] and 73,760 IU/ml (IQR: 3,269 -
805,345), respectively. Seventy-five percent (n = 33) of
individuals with HIV co-infection were on antiretroviral
therapy at the time of HCV detection.
Factors associated with ALT and HCV RNA levels
Factors associated with ALT levels (Additional file 1:
Table S2) and HCV RNA levels (categorised by tertile,
Additional file 1: Table S3) were assessed. Male gender,
older age, symptomatic HCV, HIV co-infection, esti-
mated duration of infection <26 weeks, and higher HCV
RNA levels were significantly associated with higher
ALT levels (Additional file 1: Table S2).
Distributions of gender, age and ALT levels were sig-
nificantly different across HCV RNA tertiles while male
gender, older age, HIV co-infection, and higher ALT
levels were significantly associated with HCV RNA levels
>400,000 IU/mL (Additional file 1: Table S3).
Correlation of ALT and HCV RNA levels with cytokines
and chemokines
Correlation of ALT and HCV RNA levels with plasma
cytokine and chemokine levels is summarized in Table 2.
ALT levels were positively correlated with IP-10 levels
(Pearson’s r = 0.43, P < 0.001; Fig. 1a) and MIP-1β levels
(Pearson’s r = 0.29, P = 0.001; Fig. 1b). Correlation of ALT
levels with IP-10 levels was stronger than that with MIP-
1β levels. HCV RNA levels were also positively correlated
with IP-10 levels (Spearman’s rho = 0.44, P < 0.001) and
MIP-1β levels (Spearman’s rho =0.43, P = 0.001). Mean
IP-10 levels (P < 0.001; Fig. 1c) and mean MIP-1β levels
(P < 0.001, Fig. 1d) were significantly different between
HCV RNA tertiles with increasing trends in means
being observed from the lowest tertile to the top tertile.
IP-10 and MIP-1β were selected for further analysis. In
unadjusted linear regression analyses using IP-10 levels as
the outcome variable, higher ALT levels (β = 0.21; 95 %
CI: 0.13, 0.30; P < 0.001) and HCV RNA >400,000 IU/mL
(vs. < 8,500 IU/mL; β = 0.27; 95 % CI: 0.17, 0.37; P < 0.001)
were significantly associated with higher IP-10 levels
(Table 3). In a model adjusting for sex, age, estimated
duration of infection, symptomatic infection, HIV co-
infection, interferon-lambda rs12979860 genotype,
HCV genotype, and assay run, higher ALT levels (ad-
justed β = 0.20; 95 % CI: 0.07, 0.32; P = 0.002) and HCV
RNA >400,000 IU/mL (vs. < 8,500 IU/mL; adjusted β =
0.16; 95 % CI: 0.03, 0.28; P = 0.014) remained independ-
ently associated with higher IP-10 levels (Table 3).
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Using MIP-1β levels as the outcome variable in un-
adjusted linear regression analyses, higher ALT levels (β =
0.16; 95 % CI: 0.06, 0.26; P = 0.001) and higher HCV RNA
levels were significantly associated with higher MIP-1β
levels, while mean MIP-1β levels significantly increased by
HCV RNA tertiles (8,500-400,000 vs. < 8,500 IU/mL: β =
0.14; 95 % CI: 0.02, 0.26; P = 0.020; >400,000 vs. <
8,500 IU/mL: β = 0.25; 95 % CI: 0.13, 0.36; P < 0.001;
Table 3). In a model adjusting for sex, age, estimated dur-
ation of infection, symptomatic infection, HIV co-
infection, interferon-lambda rs12979860 genotype, HCV
genotype, and assay run, only HCV RNA >400,000 IU/
mL (vs. < 8,500 IU/mL; adjusted β = 0.16; 95 % CI: 0.01,
0.31; P = 0.036) remained significantly associated with
higher MIP-1β levels. Mean MIP-1β levels was not
significantly different between HCV RNA levels 8,500-
400,000 IU/mL vs. < 8,500 IU/mL although an increas-
ing trend in mean MIP-1β levels by HCV RNA tertiles
was observed (Table 3).
In a sensitivity analysis, the correlations of IP-10 and
MIP-1β with ALT and HCV RNA levels were assessed,
stratified by HIV co-infection status (Additional file 1:
Table S4). In both groups of HCV mono-infection and
HCV/HIV co-infection, higher ALT levels and HCV
RNA >400,000 IU/mL were significantly associated with
higher IP-10 levels. The correlation of ALT with IP-10
levels was relatively stronger in HCV/HIV co-infection
group (β = 0.26; 95 % CI: 0.10, 0.41) compared to that in
HCV mono-infection group (β = 0.17; 95 % CI: 0.06, 0.28).
Higher ALT and HCV RNA levels were significantly
associated with higher MIP-1β levels in HCV mono-
infection group. In HCV/HIV co-infection, only HCV
RNA >400,000 IU/mL was significantly associated with
higher MIP-1β levels.
In another sensitivity analysis, all cytokines and che-
mokines were included in a linear regression model with
ALT being the outcome variable. In adjusted analysis,
IP-10 and MIP-1β were the only cytokines significantly
associated with ALT (P < 0.001 and P = 0.002, respect-
ively). A logistic regression model was also developed
with HCV RNA (≤400,000 IU/mL vs. >400,000 IU/mL)
as the outcome variable and all cytokines and chemo-
kines as the study variables. In adjusted analysis, higher
IP-10 and MIP-1β were significantly associated with
HCV RNA > 400,000 IU/mL (P < 0.001 and P = 0.004,
respectively).
Discussion
This study assessed the association of ALT and HCV RNA
levels with plasma levels of several pro-inflammatory and
pro-fibrogenic cytokines and chemokines in recent HCV
infection. Higher ALT levels were independently associ-
ated with higher IP-10 levels while high HCV RNA levels
(i.e., >400,000 IU/mL) were independently associated with
higher IP-10 and MIP-1β levels. These findings suggest
that the potential role of IP-10 and MIP-1β in HCV
immuno-pathogenesis starts from acute phase of infec-
tion, improving our understanding of HCV immuno-
pathogenesis.
This study identified independent associations between
higher ALT and HCV RNA levels with higher IP-10 levels
in acute HCV infection. IP-10 (CXCL10) and its unique
receptor CXCR3 have important roles in recruitment of
monocytes, macrophages, T lymphocytes, natural killer
cells, and dendritic cells to the inflamed tissue (reviewed
in [24]). The role of IP-10 in the recruitment of activated
T cells is particularly important in immuno-pathogenesis
of HCV infection given the central role of innate and
adaptive immune response in controlling HCV replication
Table 1 Baseline characteristics of ATAHC participants with
detectable HCV RNA at the time of acute HCV detection
Number (%)









infection at acute HCV detection
<26 weeks 69 (59)









Median ALT level at acute
HCV detection, IU/L (IQR)
145 (73–385)
Median HCV RNA level at acute
HCV detection, IU/mL (IQR)
73,760 (3,269-805,345)
HCV genotype
Genotype 1 67 (57)
Genotype 2 6 (5)
Genotype 3 40 (34)
Other genotypesa 2 (2)
Unknown genotype 2 (2)
Abbreviation: IQR inter-quartile range, aIncluding genotype 4 (n = 1) and mixed
genotype (n = 1)
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in acute infection and in progression of liver disease in
chronic infection [8, 25, 26]. The role of IP-10 in
immuno-pathogenesis of HCV infection has been well-
defined given the evidence demonstrating the elevation of
plasma IP-10 levels after HCV acquisition, potentially link-
ing IP-10 elevation to innate immunity [20–22], and the
association of plasma levels and/or intrahepatic expression
of IP-10 with spontaneous HCV clearance in acute
Table 2 Correlation of ALT and HCV RNA levels with cytokine and chemokine concentrations in ATAHC participants with detectable
HCV RNA at the time of acute HCV detection (n = 117)
Cytokine ALT HCV RNA
Pearson’s correlation coefficienta P Spearman’s rhob P
IL-1β −0.05 0.594 −0.02 0.800
IL-2 −0.16 0.089 0.03 0.755
IL-4 0.07 0.459 −0.03 0.761
IL-6 −0.07 0.436 0.13 0.179
IL-8 0.08 0.400 0.20 0.029
IL-10 0.04 0.668 −0.07 0.460
IL-17A −0.05 0.609 0.00 0.998
IL-17 F −0.13 0.180 0.08 0.388
IL-18 0.02 0.848 −0.06 0.540
IL-21 0.05 0.629 0.01 0.943
IL-22 0.03 0.735 0.08 0.400
IL-25 0.01 0.921 0.05 0.629
IL-31 −0.12 0.198 −0.06 0.541
IL-33 0.00 0.982 0.00 0.973
IFN-γ −0.01 0.904 −0.09 0.359
TNF-α −0.03 0.780 0.11 0.240
TRAIL −0.01 0.912 −0.15 0.118
sCD40L 0.04 0.680 0.06 0.539
Eotaxin (CCL11) 0.06 0.534 0.05 0.574
IP-10 (CXCL10) 0.43 <0.001 0.44 <0.001
MCP1 (CCL2) 0.18 0.049 0.13 0.173
MIP-1β (CCL4) 0.29 0.001 0.43 <0.001
RANTES (CCL5) 0.11 0.232 0.01 0.897
Median (IQR)c P Median (IQR)d P
IL-23 0.066 0.860
BLL (n = 30) 278 (109–498) 84,615 (6,538-692,308)
Quantified (n = 86) 130 (67–325) 74,380 (2,218-826,923)
IFN-γ2 0.315 0.277
BLL (n = 95) 153 (82–355) 67,308 (2,785-634,615)
Quantified (n = 21) 130 (54–385) 364,433 (8,654-1,288,462)
TNF-β 0.384 0.174
BLL (n = 111) 145 (73–423) 88,756 (2,885-826,923)
Quantified (n = 6) 125 (70–254) 11,442 (5,836-14,423)
MIP-1α (CCL3) 0.048 0.170
BLL (n = 52) 115 (54–296) 41,752 (2,732-395,529)
Quantified (n = 65) 217 (77–486) 88,756 (3,519-1,057,692)
Abbreviation: IQR inter-quartile range, BLL below lower limit of quantification
aALT log10 IU/L, Cytokines log10 pg/mL,
bHCV RNA IU/mL, Cytokines pg/mL, cALT IU/L, dHCV RNA IU/mL
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Fig. 1 Association of ALT and HCV RNA levels with IP-10 and MIP-1β levels in ATAHC participants with detectable HCV RNA at the time of acute
HCV detection (n = 117). (a) Distribution of IP-10 levels by ALT levels (Pearson’s r = 0.43, P < 0.001); (b) Distribution of MIP-1β levels by ALT levels
(Pearson’s r = 0.29, P = 0.001); (c) Distribution of IP-10 levels by HCV RNA tertiles (P between groups < 0.001); (d) Distribution of MIP-1β levels by
HCV RNA tertiles (P between groups < 0.001). Oblique lines in A and D represent the best fit linear line. Horizontal lines in C and D represent the
means cytokines levels in each subgroup
Table 3 Unadjusted and adjusted models assessing the correlation of plasma IP-10 and MIP-1β levels (log pg/mL) with ALT and
HCV RNA levels in ATAHC participants with detectable HCV RNA at the time of acute HCV detection
Unadjusted model Adjusted model*
Estimated Mean difference** (95 % CI) P Estimated Mean difference** (95 % CI) P
IP-10 level, log pg/mL
ALT level, log IU/L 0.21 (0.13, 0.30) <0.001 0.20 (0.07, 0.32) 0.002
HCV RNA level
<8,500 IU/mL Reference Reference
8,500 - 400,000 IU/mL 0.03 (−0.07, 0.14) 0.512 −0.05 (−0.17, 0.07) 0.414
>400,000 IU/mL 0.27 (0.17, 0.37) <0.001 0.16 (0.03, 0.28) 0.014
MIP-1β level, log pg/mL
ALT level, log IU/L 0.16 (0.06, 0.26) 0.001 0.09 (−0.06, 0.24) 0.224
HCV RNA level
<8,500 IU/mL Reference Reference
8,500 - 400,000 IU/mL 0.14 (0.02, 0.26) 0.020 0.10 (−0.04, 0.24) 0.165
>400,000 IU/mL 0.25 (0.13, 0.37) <0.001 0.16 (0.01, 0.31) 0.036
*Adjusted for variables associated with the outcome cytokine (i.e., IP-10 or MIP-1β), ALT or HCV RNA levels (P < 0.200) in unadjusted analysis, including sex, age,
symptomatic acute HCV, estimated duration of infection, HIV co-infection, Interferon lambda rs12979860 genotype, HCV genotype, and assay run; n = 113; R2 = 0.40
(for the IP-10 model); R2 = 0.28 (for the MIP-1β model)
**β coefficient
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infection [27, 28] and with interferon-induced viral
control in chronic infection [13, 29, 30]. Further, IP-10
is suggested to have a role in development of hepatic
necro-inflammation in chronic HCV infection given
that several studies demonstrated an association be-
tween increased plasma IP-10 levels [9–11, 13, 29, 31]
and upregulated intra-hepatic IP-10 expression [17, 32]
with greater inflammation grade and/or fibrosis stage in
liver biopsy among individuals with chronic HCV infec-
tion. In one study of individuals with chronic HCV and
paired liver biopsies, plasma IP-10 levels at the time of
liver biopsy were predictive of the development of
fibrosis 3–5 years later [33]. However, the mechanism
by which IP-10 exerts its role in the development of
HCV-induced hepatic necro-inflammation is not well
understood. Our findings in this current study demon-
strated independent associations between higher IP-10
levels with higher ALT and HCV RNA levels in the set-
ting of acute infection which is consistent with previous
work [22, 28]. One longitudinal study describing
dynamic changes of ALT and cytokines in nine individ-
uals with acute HCV infection demonstrated a positive
correlation between plasma IP-10 levels and the follow-
ing week ALT levels, suggesting that an increase in IP-
10 levels was associated with a subsequent increase in
ALT levels [22]. In the setting of chronic HCV, similar
correlations have been identified between plasma IP-10
levels with ALT [9–12] and HCV RNA levels [11, 13].
Taken together, these data suggest that the potential role
of IP-10 in HCV-induced hepatic necro-inflammation
might be related to both HCV cytotoxicity and liver in-
flammation. Further research is required to understand
whether higher IP-10 levels early during acute HCV infec-
tion are predictive of subsequent fibrosis progression in
chronic infection.
Our findings identified positive correlations between
plasma MIP-1β levels and both ALT and HCV RNA
levels in unadjusted analysis. However, in adjusted ana-
lysis higher plasma MIP-1β levels only remained associ-
ated with high HCV RNA levels (>400,000 IU/mL),
suggesting that MIP-1β may be produced in response to
HCV replication rather than as a result of liver inflam-
mation, as measured by ALT elevation. This hypothesis
is supported by in vitro data demonstrating that MIP-1β
was induced in response to HCV RNA replication [34].
MIP-1β (CCL4) is a strong chemoattractant for T lym-
phocytes, monocytes, natural killer cells, and dendritic
cells through interactions with CCR5, in particular and
also with several other receptors including CCR1, CCR2
and CCR3 (reviewed in [8]). Increased MIP-1β levels in
plasma [9, 35] and in hepatocytes [9, 32] have been dem-
onstrated in individuals with chronic HCV infection
compared to uninfected individuals. There are limited
data investigating the role of MIP-1β in immuno-
pathogenesis of HCV infection during acute infection. In
one study of ten individuals with acute HCV infection,
70 % of participants exhibited an elevation in plasma
MIP-1β levels after HCV acquisition [21]. However, an-
other study, investigating nine individuals with acute
HCV infection, showed no substantial change in plasma
MIP-1β levels following infection, suggesting a limiting
role for MIP-1β in lymphocyte recruitment during acute
phase of HCV infection [22].
Data on the role of MIP-1β in development of necro-
inflammation of the liver are also not consistent. In one
longitudinal study, slow progressing liver fibrosis in
HCV infection was associated with persistently lower
MIP-1β plasma levels from acute to chronic infection
[6]. Further, up-regulation of intra-hepatic CCR5 has
been shown in fibrotic and cirrhotic livers [36, 37], while
MIP-1β serum concentration was higher in individuals
with chronic liver diseases compared to healthy controls
and also was higher in cirrhotic individuals compared to
those without cirrhosis [36]. On the other hand, in other
studies, no association was found between intra-hepatic
expression [32] or plasma levels [10] of MIP-1β and liver
inflammation or fibrosis. One study demonstrated that
while incompetent CCR5 due to a polymorphism in
CCR5 gene (CCR5-Δ32) was associated with mild portal
inflammation, it was contradictorily associated with se-
vere liver fibrosis [38]. This current study indicated a
significant association between higher plasma MIP-1β
levels and high HCV RNA levels (but not with high ALT
levels) in acute infection. Similarly, although in the set-
ting of chronic HCV, one study identified that increased
plasma MIP-1 β levels were associated only with higher
HCV RNA levels [9]. Taken together, it seems HCV may
drive MIP-1β and any probable role of MIP-1β in liver
necro-inflammation might be due to the HCV cytotox-
icity, given that serum HCV RNA levels are an indirect
reflection of intra-hepatic HCV replication. The mech-
anism linking high HCV replication to increased MIP-1β
production remains to be elucidated.
This study had several limitations. First, this dataset was
cross-sectional, and cytokine levels were measured at the
first available HCV RNA-detectable sample, which varied
in relation to the likely time since the estimated date of in-
fection. Given this cross sectional design, it was not pos-
sible to longitudinally measure the levels of cytokines
during acute HCV infection. Second, given the number of
samples in this study, the cytokines and chemokines were
run on two separate days and some variation was found
between assay runs. However, distributions of IP-10 and
MIP-1β were comparable between two assay runs and the
association between ALT and HCV RNA levels and these
two cytokines were unchanged after adjusting for assay
run in the analyses. Third, cytokine and chemokine con-
centrations were measured from plasma samples, so it is
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possible that the levels in the blood might not reflect
hepatic levels. However, a strong correlation has been
demonstrated between plasma IP-10 levels and intra-
hepatic expression of IP-10 mRNA in chronic HCV
infection [30]. Fourth, there are many other cytokines
and chemokines not assessed in this current study. As
such, this study is not able to fully explain the complex
signalling pathways of HCV RNA replication, liver
inflammation and immuno-pathogenesis of HCV infec-
tion. Fifth, there is evidence indicating that IP-10 can
undergo cleavage to form an inactive version of the
protein that may act as a dominant negative by binding
the CXCR3 receptor without leading to chemotaxis and
can act as an antagonist [39, 40]. Measurement of the
cleaved and uncleaved fractions of IP-10 requires storage
of plasma in specialized tubes to avoid post-collection
cleavage. Unfortunately, the samples used in this study
were not stored to allow for measurement of cleaved IP-
10, so this could not be evaluated. Sixth, it is possible that
long-term storage may have led to reduced levels of some
cytokines and chemokines [41]. However, participant sam-
ples were stored identically with a minimal number of
freeze-thaws, so it is not anticipated that this would have
had an effect on the observed results between the associ-
ation of ALT and HCV RNA levels with IP-10 and MIP-
1β levels. Further, data on liver fibrosis levels were not
available in our participants. As such, we were not able to
assess the association of IP-10 and MIP-1β levels with
liver fibrosis in this study. Lastly, given that 38 % of our
participants were co-infected with HIV, we used two
approaches to control for the potential effect of HIV on
ALT and HCV RNA levels with IP-10 and MIP-1β levels,
including stratification and adjustment in multivariate
analysis. However, in both analyses, IP-10 and MIP-1β
levels were associated with ALT and HCV RNA levels, re-
gardless of HIV status.
Conclusion
In conclusion, this study demonstrated that during re-
cent HCV infection, higher ALT levels were associated
with increased IP-10 levels, while high HCV RNA levels
were associated with increased plasma IP-10 and MIP-
1β levels. These data improve our understanding of
immuno-pathogenesis of HCV infection, suggesting that
the potential roles of IP-10 and MIP-1β in HCV
immuno-pathogenesis start from acute phase of infec-
tion, possibly in relation with liver inflammation (IP-10)
and HCV cytotoxicity (IP-10 and MIP-1β). These
hypotheses need to be investigated through further
research to elucidate the mechanism linking IP-10 and
MIP-1β with HCV replication and liver inflammation.
Further research is also needed to investigate whether
higher IP-10 and MIP-1β levels during acute HCV
infection are predictive of subsequent fibrosis progres-
sion in chronic infection.
Methods
Study participants
The Australian Trial in Acute Hepatitis C (ATAHC) was
a prospective study of the natural history and treatment
of recently acquired HCV infection. The ATAHC study
design has been described previously in detail [42].
Recent HCV infection (i.e., acute or early chronic infec-
tion) was defined by an initial positive anti-HCV anti-
body test within 6 months of enrolment and either 1) a
negative anti-HCV antibody test within two years prior
to the initial positive anti-HCV antibody test or 2) acute
clinical hepatitis within 12 months before the initial
positive anti-HCV antibody result. Acute clinical infec-
tion was defined by symptomatic seroconversion illness
or peak ALT levels greater than 400 IU/L at or before
the time of HCV diagnosis.
In the current study, ATAHC participants with avail-
able plasma samples and HCV RNA detected at the time
of HCV detection were included. Cytokines and chemo-
kines were measured in plasma samples at the time of
HCV detection using a multiplex assay (see below). The
ATAHC protocol was reviewed and approved by Human
Research Ethics Committees of St. Vincent’s Hospital,
Sydney and the University Health Network, and all par-
ticipants provided informed written consent. ATAHC
was performed according to the World Medical Associ-
ation Declaration of Helsinki. The study was registered
with clinicaltrials.gov registry (NCT00192569).
Measurement of plasma cytokines and chemokines
Three human cytokine multiplex bead array assay kits
utilizing technology licensed by Luminex were purchased
from Bio-Rad (Gladesville, Australia) to measure the fol-
lowing cytokines and chemokines:
 Measured with Bio-Plex human TH17 15-plex:
interleukin-1 beta (IL-1β), IL-4, IL-6, IL-10, IL-17A,
IL-17 F, IL-21, IL-22, IL-23, IL-25,IL-31, IL-33,
interferon-gamma (IFN-γ), soluble CD40 ligand
(sCD40L), and tumor necrosis factor alpha (TNF-α)
 Measured with Bio-Plex human cytokine Group I 9-
plex: IL-2, IL-8, eotaxin-1 (or CCL11), IFN-γ,
interferon-gamma inducible protein-10 (IP-10, or
CXCL10), monocyte chemotactic protein 1 (MCP-1,
or CCL2), macrophage inflammatory protein 1
alpha (MIP-1α, or CCL3), MIP-1β (or CCL4), and
regulated upon activation normal T-cell expressed
and presumably secreted (RANTES or CCL5)
 Measured with Bio-Plex human cytokine Group II
3-plex: IL-18, TNF-β, and TNF-related apoptosis-
inducing ligand (TRAIL, or TNFSF10).
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The protocol was performed as per the manufacturer’s
instructions as previously described [43, 44], with sam-
ples centrifuged at 10,000 × g for 10 minutes at 4 °C to
remove platelets and precipitates, after which the super-
natants were diluted four times with assay diluents. The
assay was performed in a 96-well filter plate, using all
the assay components provided. All incubation steps
were performed at room temperature and in the dark to
protect the beads from light and washes were performed
using a vacuum manifold. For the detection of cytokines
and chemokines, the samples were then incubated for
10 minutes while shaken at 850 rpm with streptavidin
conjugated to the fluorescent protein, Streptavidin-PE.
After subsequent washing in order to remove the un-
bound Streptavidin-PE, the beads (minimum of 50 beads
per cytokine) were analysed on the Bio-Plex 200 instru-
ment, which monitored the spectral properties of the
beads while simultaneously measuring the amount of
fluorescence associated with R-phycoerythrin. The raw
data was analysed using the Bio-Plex Manager software,
v6.1 (Bio-Rad) [21]. Cytokine standards supplied by the
manufacturer were used to calculate the concentrations
of the samples. The lower limits of quantification for all
cytokines and chemokines are summarized in Additional
file 1: Table S1. Due to the large number of samples,
they were split randomly in two sets and processed on
two 96 well plates (assay runs). Each day, one set was
run for all three cytokines and chemokines panels. Lot
numbers for multiplex bead array assay kits and proced-
ure used were identical between assay runs.
HCV RNA and genotype testing
The presence of HCV RNA was assessed with a qualita-
tive HCV RNA assay (TMA assay; Versant, Bayer,
Australia; lower limit of detection, 10 IU/mL) and if
positive HCV RNA levels were assesses with a quantita-
tive HCV RNA assay (Versant HCV RNA 3.0; Bayer,
Australia; lower limit of detection, 615 IU/mL). HCV
genotype (Versant LiPa; Bayer, Australia) was assessed
for participants with detectable HCV RNA.
Statistical analysis
Log10 transformed values of ALT levels (log10 IU/L) and
cytokines levels (log10 pg/mL) were used in analysis
given the distribution of the actual values were not nor-
mal. Given that HCV RNA levels (IU/mL) and log10
transformation of HCV RNA levels (log10 IU/mL) were
not normally distributed, non-parametric statistical
methods were the basis of analysis of HCV RNA levels.
The correlation of ALT with plasma cytokine levels
were assessed using Pearson correlation, while the cor-
relation of HCV RNA with plasma cytokine levels were
assessed using Spearman’s rank-order correlation. If a
plasma cytokine level was below the lower level of
quantification, the midpoint between zero and the lowest
level of quantification was imputed (Additional file 1:
Table S1). Plasma levels of four cytokines (IL-23, IFN-γ,
TNF-β, and MIP-1a) were below the level of quantifica-
tion in ≥20 % of individuals, for each of those the distribu-
tion of ALT and HCV RNA levels were compared
between individuals with quantifiable and those with un-
quantifiable cytokine levels (Wilcoxon-Mann–Whitney
test).
Overall, the association of ALT and HCV RNA levels
with 27 plasma cytokines levels were assessed. Whether
adjustments are needed for multiple comparisons is a
matter of controversy given that multiple comparison
testing might inflate type 1 error while adjustments for
multiple comparisons inflate type 2 error [45–48]. To
account for multiple comparisons, a moderately conser-
vative significance level (alpha = 0.01) was used. In a
sensitivity analysis, using Bonferroni correction for mul-
tiple comparisons, an alpha = 0.05/27 = 0.002 was also
used, but the findings were similar.
Cytokines demonstrating significant correlations with
ALT and/or HCV RNA levels were included in linear
regression analysis. Linear regression models were fit to
assess the correlation of ALT levels (log IU/L) and
HCV RNA levels (categorised by tertile: <8,500 IU/mL,
8,500-400,000 IU/mL, >400,000 IU/mL) with each
plasma cytokine levels (log pg/mL). In the adjusted
models, the correlation of ALT and HCV RNA levels
with cytokine levels was adjusted for potential con-
founders including sex, age, estimated duration of
infection at acute HCV detection, symptomatic illness
at acute HCV detection, HIV co-infection, interferon-
lambda rs12979860 genotype, HCV genotype, and assay
run. Potential confounders were adjusted for, including
variables associated with either of ALT, HCV RNA, or
cytokine levels in this study (P < 0.200). To account for
potential unmeasured confounders introduced by dif-
ferent assay runs and sample set, the models were also
adjusted for assay run. All analyses were performed
using Stata v12.0 (College Station, TX, United States).
Additional file
Additional file 1: Supplementary Material. (DOCX 38 kb)
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